Kim Margolin, MD

Kim Margolin, MD

Department of Medicine
Division of Oncology

Mailing Address

Seattle Cancer Care Alliance
825 Eastlake Ave E
Seattle, WA 98109

Admin Contact

Sandra Bergevin
Fax: 206.288.6681

Specialty / Expertise

Melanoma, Renal, and Germ Cell Cancer

Research Interests

Dr. Margolin's research interests involve improving the therapy for melanoma based on understanding the biology and immunology of this disease. Her collaborations extend through the University of Washington and Fred Hutchinson Cancer Research Center to other U.S. sites working on clinical trials for melanoma using immunotherapy and new molecularly-targeted drugs. She has also maintained an interest in the biology and treatment of germ cell cancer and participates in national and international collaborations in this area.

Current Research Projects


Role: PI
Funding Source: Bristol-Meyers Squibb Company
A Multi-Center Phase II Study to evaluate tumor response to Ipilimumab (BMS-734016) Monotherapy in subjects with melanoma brain metastases. Published Phase II 2012.

Role: PI
Funding Source: Bristol-Meyers Squibb Company
Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group. Accrual completed.

Role: PI
Funding Source: GlaxoSmithKline Biologicals
An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma. Manuscript in preparation. Margolin will be co-author.

Role: PI
Funding Source: Hoffman-LaRoche, Inc
A randomized, open-label, controlled, multicenter, phase III study in previously untreated patients with unresectable stage IIIC or stage IV melanoma with V600E BRAF Mutation Receiving RO5185426 or Dacarbazine Completed and published. Provided the basis for FDA approval of vemurafenib.

Role: PI
Funding Source: Genentech, Inc.
ML25597: A Single-Arm, Open-Label, Expanded Access Study of RO5185426 In Patients with Metastatic Melanoma. Completed.

Role: PI
Funding Source: Beth Israel Deaconess Medical Center
The High-Dose Aldesleukin (Il-2) "Select" Trial: A Prospective Tissue Collection Protocol To Investigate Predictive Models Of Response To High Dose Il-2 Treatment In Patients With Advanced Melanoma.

Role: PI
Funding Source: Bristol-Meyers Squibb Company
A Randomized, Blinded, Phase 2 Dose-Ranging Study of BMS-936558 (MDX-1106) in Subjects with Progressive Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy. Completed, under analysis.

Role: PI
Funding Source: GlaxoSmithKline, Inc
BRF113929: A Phase II Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects with BRAF Mutation-Positive Metastatic Melanoma to the Brain. Completed and published.

Role: PI
Funding Source: Genentech, Inc
An open-label, single-arm, phase II, multicenter study to evaluate the efficacy of vemurafenib in metastatic melanoma patients with brain metastases.

Role: PI
Funding Source: Bristol-Meyers Squibb Company
A Randomized Double-Blind Phase III Study of Ipilimumab Administered at 3 mg/kg vs at 10 mg/kg in Subjects with Previously Treated or Untreated Unresectable or Metastatic Melanoma. Completed and under analysis.

Role: PI
Funding Source: Altor Biosciences Clinical and Immunologic
Effects of a Novel Interleukin-15/Interleukin-15aSu/Fc Fusion Complex in Patients with Advanced Melanoma


Role: PI
Funding Source: Merck Randomized
Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma

Role: PI
Funding Source: Bristol Myers Squibb
CA184-338: A Multi-Site Retrospective Observational Study of US Patients With Unresectable or Metastatic Melanoma Receiving Ipilimumab (Yervoy) as First-Line Therapy

Role: PI
Funding Source: GlaxoSmithKline Biologicals
BRF115532: A phase III randomized double blind study of dabrafenib (GSK2118436) in COMBInation with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 mutation-positive melanoma after surgical resection

Role: PI
Funding Source: Merck
MK3475-006: A Multicenter, Randomized, Controlled, Two-Arm, Phase III Study to Evaluate the Safety and Efficacy of MK-3475 Compared to Ipilimumab in Patients with Advanced Melanoma


Dr. Margolin received her MD from Stanford University, Stanford, CA. She completed her Internal Medicine Residency at Yale New Haven Hospital, New Haven, CT. She was a Post-Doctoral Fellow in Hematology/Oncology at University of California, Sand Diego, San Diego, CA. She was a Post-Doctoral Fellow in Hematology and Bone Marrow Transplantation at City of Hope National Medical Center, Duarte, CA.

Selected Publications

Margolin KA, Rayner AA, Hawkins MJ Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Doroshow JH, Jaffee HS, Roper M. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol. 7 (4): 486-498, 1989. PMID 2647914.

Margolin, K., Green, S., Osborne, K, Doroshow, J.H., Akman, S.A., Leong, L.A., Morgan, R.J., Raschko, J.W., Somlo, G., Hutchins, L. and Upchurch, C.  Phase II trial of 5-fluorouracil and high-dose folinic acid as first or second-line therapy for advanced breast cancer.  Am J Clin Oncol. 17 (2): 175-180, 1994, PMID 8141112.

Margolin, K., Liu, P.Y., Flaherty, L.E., Sosman, J.A., Walker, M.J., Smith, J.W. III, Fletcher, W.S., Weiss, G.R., Unger, J.M., Sondak, V.K.  Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.  J Clin Oncol. 16 (2): 664-669, 1998, PMID 9469356.

Margolin KA, Aronson FR, Sznol M, Atkins MB, Ciobanu N, Fisher RI, Weiss GR, Doroshow JH, Bar MH, Hawkins MJ. Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma. J Immunother. 10(3): 214-220, 1991. PMID 1868045.

Margolin KA, Doroshow JH, Akman SA, Leong LA, Morgan RJ, Somlo G, Raschko J, Pereira C, Yonemoto L, Ahn C. Phase II trial of cisplatin and alpha-interferon in advanced malignant melanoma. J Clin Oncol. 10(10): 1574-1578, 1992. PMID 1403037.

Margolin KA, Aronson F, Sznol M, Atkins MB, Gucalp R, Fisher RI, Sunderland M, Doroshow JH, Ernest ML, Mier JW. Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. J. Immunother Emphasis Tumor Immunol.15(2):147-153, 1994. PMID 8136948.

Margolin KA, Atkins J, Sparano J, Sosman J, Weiss G, Lotze M, Doroshow J, Mier, O’Boyle K, Fisher R, Campbell E, Rubin J, Federighi D, Bursten S. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma. Clin Cancer Res. 3(4): 565-572, 1997. PMID 9815721.

Margolin KA, Van Besien K, Wright C, Niland J, Champlin R, Fung HC, Kashyap A, Molina A, Nademanee AP, O’Donnell MR, Parker P, Smith E, Spielberger R, Somlo G, Snyder D, Stein A, Woo D, Thomas M, Sniecinski I, Forman SJ. Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma. Biol Blood Marrow Transplant. 5(1): 36-45, 1999. PMID 10232739.

McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB. Randomized Phase III Trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 23(1): 133-141, 2005. PMID 15625368.

Margolin KA, Doroshow JH, Frankel P, Chow W, Leong LA, Lim D, McNamara M, Morgan RJ, Shibata S, Somlo G, Twardowski P, Yen Y, Kogut N, Schriber J, Alvarnas J, Stalter S. Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer. Biol Blood Marrow Transplant. 11(11): 903-911, 2005. PMID 16275593.

Rini BI, Halabi S,Barrier R, Margolin KA, Avigan D, Logan T, Stadler WM, McCarthey PL, Linker CA, Small EJ; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; Southwestern Oncology Group. (2006). Adoptive immunotherapy by allogenic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. Biol Blood Marrow Transplant. 12(7): 778-785, 2006. PMID 16785067.

Margolin KA, Atkins MB, Dutcher JP, Ernstoff MS, Smith JW 2nd, Clark JI, Baar J, Sosman J, Weber J, Lathia C, Brunetti J, Cihon F, Schwartz B. Phase I Trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer. Clin Cancer Res.13(11): 3312-3319, 2007. PMID 17545537.

Atkins MB, Sosman JA, Agarwala S, Logan T, Clark JI, Ernstoff MS, Lawson D, Dutcher JP, Weiss G, Curti B, Margolin KA. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer. 113(8): 2139-2145, 2008. PMID 18792064.

Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13 (5):459-465, 2012. PMID 22456429.

Margolin KA, Moon J, Flaherty LE, Lao CD, Akerley WL 3rd, Othus M, Sosman JA, Kirkwood JM, Sondak VK, Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (SWOG S0438). Clin Cancer Res. 18 (4): 1129-37, 2012. PMID 22228638.

Tarhini, A.A., Frankel, P., Margolin, K.A., Christensen, S., Ruel, C., Shipe-Spotloe, J., Gandara, D.R., Chen, A., Kirkwood, J.M. Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin. Clin Cancer Res, 6574-81, 2011.

Margolin KA, Moon J, Flaherty LE, Lao CD, Akerley WL 3rd, Othus M, Sosman JA, Kirkwood JM, Sondak VK. Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (SWOG S0438). Clin Cancer Res, 18: 1129-37, 2012.

Chapuis AG, Thompson JA, Margolin KA, Rodmyre R, Lai IP, Dowdy K, Farrar EA, Bhatia S, Sabath DE, Cao J, Li Y, Yee C. Transferred Melanoma-Specific CD8+ T Cells Persist, Mediate Tumor Regression and Acquire Central Memory Phenotype. Proc Nat Acad Sci, 109: 4592-97, 2012.

Pal SK, Yamzon J, Sun V, Carmichael C, Saikia J, Ferrell B, Frankel P, Hsu J, Twardowski P, Stein CA, Margolin K. Paclitaxel-Based High-Dose Chemotherapy with Autologous Stem Cell Rescue for Relapsed Germ Cell Tumor: Clinical Outcome and Quality of Life in Long-Term Survivors. Clin Genitourin Cancer, [Epub ahead of print] 2012.

Bhatia S, Moon J, Margolin KA, Weber JS, Lao CD, Othus M, Aparicio AM, Ribas A, Sondak VK.  Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512.  PLOS ONE 7(11): e48787. 2012.

Last updated: February 2013